A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Clinical trial NCT05253651 · RECRUITING
Trial details
- NCT number
- NCT05253651
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-24
- Primary completion
- 2027-12-31
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.